Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial

Frank Smithuis, Moe Kyaw Kyaw, Ohn Phe, Thein Win, Pyay Phyo Aung, Aung Pyay Phyo Oo, Arkar Linn Naing, Mya Yee Nyo, Naing Zaw Htun Myint, Mallika Imwong, Elizabeth Ashley, Sue J Lee, Nicholas J White, Frank Smithuis, Moe Kyaw Kyaw, Ohn Phe, Thein Win, Pyay Phyo Aung, Aung Pyay Phyo Oo, Arkar Linn Naing, Mya Yee Nyo, Naing Zaw Htun Myint, Mallika Imwong, Elizabeth Ashley, Sue J Lee, Nicholas J White

Abstract

Background: Artemisinin-combination therapy (ACT) is recommended as first-line treatment of falciparum malaria throughout the world, and fixed-dose combinations are preferred by WHO; whether a single gametocytocidal dose of primaquine should be added is unknown. We aimed to compare effectiveness of four fixed-dose ACTs and a loose tablet combination of artesunate and mefloquine, and assess the addition of a single gametocytocidal dose of primaquine.

Methods: In an open-label randomised trial in clinics in Rakhine state, Kachin state, and Shan state in Myanmar (Burma) between Dec 30, 2008, and March 20, 2009, we compared the effectiveness of all four WHO-recommended fixed-dose ACTs (artesunate-mefloquine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, artemether-lumefantrine) and loose artesunate-mefloquine in Burmese adults and children. Eligible patients were those who presented to the clinics with acute uncomplicated Plasmodium falciparum malaria or mixed infection, who were older than 6 months, and who weighed more than 5 kg. Treatments were randomised in equal numbers within blocks of 50 and allocation was in sealed envelopes. All patients were also randomly assigned to receive either a single dose of primaquine 0·75 mg base/kg or not. Patients were followed up for 63 days. Treatment groups were compared by analysis of variance and multiple logistic regression. The primary outcome was the 63 day recrudescence rate. This study is registered with clinicaltrials.gov, number NCT00902811.

Findings: 155 patients received artesunate-amodiaquine, 162 artemether-lumefantrine, 169 artesunate-mefloquine, 161 loose artesunate-mefloquine, and 161 dihydroartemisinin-piperaquine. By day 63 of follow-up, 14 patients (9·4%; 95% CI 5·7-15·3%) on artesunate-amodiaquine had recrudescent P falciparum infections, a rate significantly higher than for artemether-lumefantrine (two patients; 1·4%; 0·3-5·3; p=0·0013), fixed-dose artesunate-mefloquine (0 patients; 0-2·3; p<0·0001), loose artesunate-mefloquine (two patients; 1·3%; 0·3-5·3; p=0·0018), and dihydroartemisinin-piperaquine (two patients 1·3%; 0·3-5·2%; p=0·0012). Hazard ratios for re-infection (95% CI) after artesunate-amodiaquine were 3·2 (1·3-8·0) compared with the two artesunate-mefloquine groups (p=0·01), 2·6 (1·0-6-0) compared with artemether-lumefantrine (p=0·04), and 2·3 (0·9-6·0) compared with dihydroartemisinin-piperaquine (p=0·08). Mixed falciparum and vivax infections were common: 129 (16%) had a mixed infection at presentation and 330 (41%) patients had one or more episodes of Plasmodium vivax infection during follow-up. The addition of a single dose of primaquine (0·75 mg/kg) reduced P falciparum gametocyte carriage substantially: rate ratio 11·9 (95% CI 7·4-20·5). All regimens were well tolerated. Adverse events were reported by 599 patients, most commonly vomiting and dizziness. Other side-effects were less common and were not related to a specific treatment.

Interpretation: Artesunate-amodiaquine should not be used in Myanmar, because the other ACTs are substantially more effective. Artesunate-mefloquine provided the greatest post-treatment suppression of malaria. Adding a single dose of primaquine would substantially reduce transmission potential. Vivax malaria, not recurrent falciparum malaria, is the main complication after treatment of P falciparum infections in this region.

Funding: Médecins sans Frontières (Holland) and the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme.

Copyright © 2010 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile AA=artesunate–amodiaquine. PQ=primaquine. DP=dihydroartemisinin–piperaquine. AL=artemether–lumefantrine. AM-L=loose tablet regimen of artesunate–mefloquine. AM-F=fixed-dose artesunate–mefloquine.
Figure 2
Figure 2
Comparative efficacy of the five ACT regimens against falciparum malaria in Myanmar Recurrences are recrudescence plus re-infections. AA=artesunate–amodiaquine. AL=artemether–lumefantrine. AM-F=fixed-dose artesunate–mefloquine. AM-L=loose tablet regimen of artesunate–mefloquine. DP=dihydroartemisinin–piperaquine.
Figure 3
Figure 3
Cumulative proportion of patients with vivax malaria during follow-up AA=artesunate–amodiaquine. AL=artemether–lumefantrine. AM-F=fixed-dose artesunate–mefloquine. AM-L=loose tablet regimen of artesunate–mefloquine. DP=dihydroartemisinin–piperaquine.
Figure 4
Figure 4
Effects of a single dose of primaquine on Plasmodium falciparum gametocyte carriage after artemisinin combination treatment All five ACT regimens pooled. No gametocytaemia was detected after day 42.

References

    1. WHO . Guidelines for the treatment of malaria. 2nd edn. World Health Organization; Geneva: 2010.
    1. Smithuis F, Kyaw MK, Phe O. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet. 2006;367:2075–2085.
    1. Smithuis F, van der Broek I, Katterman I. Optimising operational use of artesunate-mefloquine; a randomised comparison of four treatment regimens. Trans R Soc Trop Med Hyg. 2004;98:182–192.
    1. Smithuis F, Shahmanesh M, Kyaw MK, Savran O, Lwin S, White NJ. Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North Myanmar. Trop Med Int Health. 2004;9:1184–1190.
    1. Ashley EA, Stepniewska K, Lindegårdh N. Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2006;50:2281–2285.
    1. Price RN, Nosten F, Luxemburger C. The effects of artemisinin derivatives on malaria transmissability. Lancet. 1996;347:1654–1658.
    1. Bousema JT, Schneider P, Gouagna LC. Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum. J Infect Dis. 2006;193:1151–1159.
    1. Burgess RW, Bray RS. The effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum. Bull World Health Organ. 1961;24:451–456.
    1. Suputtamongkol Y, Chindarat S, Silpasakorn S. The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. Am J Trop Med Hyg. 2003;68:620–623.
    1. Smithuis FM, Monti F, Grundi M. In vivo sensitivity of Plasmodium falciparum to chloroquine, sulphadoxine-pyrimethamine, and mefloquine in Rakhine State, western Myanmar. Trans R Soc Trop Med Hyg. 1997;91:468–472.
    1. Brockman A, Paul RE, Anderson TJ. Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg. 1999;60:14–21.
    1. White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malaria J. 2008;11:7–9.
    1. Zwang J, Ashley EA, Karema C. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One. 2009;4:e6358.
    1. van Vugt M, Brockman A, Gemperli B. Randomised comparison of artemether-benflumetol and artesunate-mefloquine in the treatment of multi-drug resistant falciparum malaria. Antimicrob Agents Chemother. 1998;42:135–139.
    1. Okell LC, Drakeley CJ, Ghani AC, Bousema T, Sutherland CJ. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials. Malar J. 2008;7:125.
    1. Carrara VI, Sirilak S, Thonglairuam J. Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med. 2006;3:e183.
    1. MacKerras MJ, Ercole QN. Observations on the action of quinine, atebrin and plasmoquine on the gametocytes of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1949;42:455–463.
    1. Shekalaghe S, Drakeley C, Gosling R. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One. 2007;2:e1023.
    1. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75:402–415.
    1. Beutler E, Duparc S, G6PD Deficiency Working Group Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779–789.
    1. Shekalaghe SA, ter Braak R, Daou M. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A–) individuals. Antimicrob Agents Chemother. 2010;54:1762–1768.
    1. Ratcliff A, Siswantoro H, Kenangalem E. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet. 2007;369:757–765.
    1. Price RN, Simpson JA, Teja-Isavatharm P. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob Agents Chemother. 1999;43:341–346.
    1. Simpson JA, Price RN, ter Kuile FO. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin Pharmac Ther. 1999;66:472–484.
    1. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J. 2008;7(suppl 1):S8.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe